1 圣湘生物（ [Table_StockNameRptType] 688289） 公司点评 呼吸道检测持续高增长，并购拓展成长边界 | 投资评级：买入（维持） [Table_Rank] | | | | --- | --- | --- | | 报告日期： | 2025-05-04 | | | [Table_BaseData] 收盘价（元） | | 19.81 | | 近 12 个月最高/最低（元） | | 26.36/16.44 | | 总股本（百万股） | | 579 | | 流通股本（百万股） | | 579 | | 流通股比例（%） | | 100.00 | | 总市值（亿元） | | 115 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -13% 4% 20% 37% 5/24 8/24 11/24 2/25 圣湘生物 沪深300 1.【华安医药】公司点评：圣湘生物 （688289）：业绩持续高增长，呼吸 道感染检测竞争力强 2024-10-30 主要观点： [➢Table_Summary] 事件： 公司公告 2024 年年报及 2025 年一季报。2024 年，公司实现营 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is actively reducing inventory, and there are positive expectations for whisky recruitment [5][8] - The RTD (Ready-to-Drink) division is expected to return to high-quality development, focusing on optimizing marketing expenses [7] - The company's revenue for Q1 2025 was 737 million yuan, a decrease of 8.11% year-on-year, while the net profit attributable to the parent company was 181 million yuan, an increase of 7.03% [9] Financial Performance Summary - For 2024, the company reported total revenue of 3.048 billion yuan, a decrease of 6.61% year-on-year, and a net profit of 719 million yuan, down 11.15% [9] - In Q1 2025, the company achieved a gross margin of 69.7%, an increase of 1.3 percentage points year-on-year, with a notable reduction in sales expenses [9] - The company expects revenue growth of 12.7%, 13.8%, and 15.3% for the years 2025, 2026, and 2027, respectively, with net profit growth of 12.3%, 17.2%, and 17.9% for the same years [9][11] Product and Market Insights - The company is launching new whisky products, including "Bailide" blended whisky and the "Laizhou" single malt whisky series, with recruitment and distribution expected to catalyze growth in Q2 [8] - The revenue from the pre-mixed drinks and flavoring segments showed a decline of 7.17% and an increase of 6.30% year-on-year, respectively, with pre-mixed drinks accounting for 87.8% of total revenue [9]

迎驾贡酒（ [Table_StockNameRptType] 603198） 公司点评 | 系列酒与省外拖累 | | --- | ——迎驾贡酒 24 年报&25Q1 点评 | 投资评级：买入（维持） [Table_Rank] | | | | --- | --- | --- | | 报告日期： | 2025-05-04 | | | [Table_BaseData] 收盘价（元） | | 43.92 | | 近 12 个月最高/最低（元） | | 80.19/43.90 | | 总股本（百万股） | | 800 | | 流通股本（百万股） | | 800 | | 流通股比例（%） | | 100.00 | | 总市值（亿元） | | 351 | | 流通市值（亿元） | | 351 | [公司价格与沪深 Table_Chart] 300 走势比较 -50% -31% -12% 7% 26% 5/24 8/24 11/24 2/25 迎驾贡酒 沪深300 [Table_Author] 分析师：邓欣 执业证书号：S0010524010001 邮箱：dengxin@hazq.com 联系人：郑少轩 敬请参阅末页重要声明 ...

公司点评 | 静待渠道改革见效 | | --- | ——三只松鼠 25Q1 点评 主要观点： ➢ 25Q1 收入符合市场预期。 ⚫ 收入：春节错期扰动 | | | ➢ 分渠道看，线上面临高基数压力，预计营收增速同比持平。根据久谦 数据，公司 25Q1 猫京抖 GMV 合计同比下降 0.9%。线下渠道改革 顺 利 ， 预 计 同 比 实 现 双 位 数 增 长 。 去 除 春 节 影 响 ， 营 收 端 "24Q4+25Q1"合计同比增长 16.2%，仍处于快速增长。 ⚫ 利润：渠道费用投入阶段性加大 ➢ 25Q1 公司毛利率同比下降 0.66pct 至 26.74%，销售/管理/研发/财务 费率分别同比+2.41/+0.43/持平/-0.03pct。其中，毛利率下降与销售 费率上升，预计主因渠道改革导致费用投入力度加大；管理费率上升 预计主因研发中心转固导致折旧摊销费用上升。综上，公司归母净利 率同比下降 2.04pct 至 6.42%。 ⚫ 投资建议：维持"买入" ➢ 我们的观点： 公司线下渠道改革稳步推进，长尾性价比产品矩阵充分满足 BCD 类 商超需求痛点，通过并购爱折扣切入硬折扣业态，营收仍有额外增量 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is actively reducing inventory, and there are positive expectations for whisky recruitment [5][8] - The RTD (Ready-to-Drink) division is expected to return to high-quality development, focusing on optimizing marketing expenses [7] - The company's revenue for Q1 2025 was 737 million yuan, a decrease of 8.11% year-on-year, while net profit attributable to shareholders was 181 million yuan, an increase of 7.03% [9] Financial Performance Summary - For 2024, the company reported total revenue of 3.048 billion yuan, a decline of 6.61% year-on-year, and a net profit of 719 million yuan, down 11.15% [9] - In Q1 2025, the company achieved a gross margin of 69.7%, an increase of 1.3 percentage points year-on-year, with a notable reduction in sales expenses [9] - The company expects to achieve revenues of 3.434 billion yuan, 3.907 billion yuan, and 4.504 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 12.7%, 13.8%, and 15.3% [9][11] Product and Market Insights - The company is launching new whisky products, including "Bailide" blended whisky and the "Laizhou" single malt whisky series, with recruitment and distribution expected to catalyze growth in Q2 [8] - The revenue from pre-mixed drinks and flavoring segments showed a decline of 7.17% and an increase of 6.30% respectively in 2024 [9] Valuation Metrics - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 34, 29, and 25 times respectively, maintaining a "Buy" rating [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has set ambitious operational targets for 2025, aiming for a 25% year-on-year growth in new contract orders, reaching 268 billion yuan (excluding tax), and a 20% increase in revenue to 185 billion yuan [6] - In 2024, the company achieved a revenue of 15.458 billion yuan, a year-on-year increase of 24.06%, and a net profit attributable to shareholders of 2.049 billion yuan, up 31.42% [5][9] - The company is focusing on consolidating its domestic market share while expanding into key overseas markets and investing in product development and technological innovation [6] Financial Performance - In Q4 2024, the company reported a revenue of 5.051 billion yuan, a 30.20% increase year-on-year, and a net profit of 558 million yuan, up 35.73% [5] - For Q1 2025, the company achieved a revenue of 3.227 billion yuan, a 21.41% increase year-on-year, and a net profit of 446 million yuan, up 22.91% [5] - The gross profit margin for 2024 was 31.25%, an increase of 1.75 percentage points year-on-year [5] Revenue and Profit Forecast - Revenue projections for 2025-2027 are 18.680 billion yuan, 22.416 billion yuan, and 26.899 billion yuan respectively, with corresponding net profits of 2.769 billion yuan, 3.360 billion yuan, and 3.663 billion yuan [7][9] - The expected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are 20.2, 16.7, and 15.3 respectively [7]

公司点评 金盘科技（688676） 外销收入快速增长，数据中心新基建加速扩张 | 投资评级：买入（维持） | | --- | | 报告日期： 2025-05-04 | | 收盘价（元） | 31.88 | | --- | --- | | 近 12 个月最高/最低（元） 64.58/27.00 | | | 总股本（百万股） | 457 | | 流通股本（百万股） | 457 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 146 | | 流通市值（亿元） | 146 | 公司价格与沪深 300 走势比较 -60% -40% -20% 0% 20% 40% 04-30 05-31 06-30 07-31 08-31 09-30 10-31 11-30 12-31 01-31 02-28 03-31 04-30 金盘科技 沪深300 外销收入快速增长，数据中心新基建加速扩张 公司 2024 年海外销售收入 19.81 亿元，同比增长 68.26%。非新能源领 域 2024 年实现营收 37.12 亿元，同比增长 31.02%，以数据中心为代表 的新基建重要基础设施运营及数字化工厂整体解决方案 ...

公司点评 25 年经营目标彰显信心，订单目标同比高速增长 | 投资评级：买入（维持） | | | --- | --- | | 报告日期： | 2025-05-04 | | 收盘价（元） | 71.97 | | 近 12 个月最高/最低（元） | 81.81/59.66 | | 总股本（百万股） | 778 | | 流通股本（百万股） | 606 | | 流通股比例（%） | 77.89 | | 总市值（亿元） | 560 | | 流通市值（亿元） | 436 | 公司价格与沪深 300 走势比较 -20% -10% 0% 10% 20% 30% 04-30 05-31 06-30 07-31 08-31 09-30 10-31 11-30 12-31 01-31 02-28 03-31 04-30 思源电气 沪深300 分析师：张志邦 执业证书号：S0010523120004 邮箱：zhangzhibang@hazq.com 分析师：郑洋 执业证书号：S0010524110003 邮箱：zhengyang@hazq.com 思源电气（002028） 主要观点： 业绩 公司公布 2024 年年报及 2025 年 ...

金盘科技（688676） 公司点评 外销收入快速增长，数据中心新基建加速扩张 | 投资评级：买入（维持） | | | --- | --- | | 报告日期： | 2025-05-04 | | 收盘价（元） | 31.88 | | 近 12 个月最高/最低（元） 64.58/27.00 | | | 总股本（百万股） | 457 | | 流通股本（百万股） | 457 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 146 | | 流通市值（亿元） | 146 | 公司价格与沪深 300 走势比较 -60% -40% -20% 0% 20% 40% 04-30 05-31 06-30 07-31 08-31 09-30 10-31 11-30 12-31 01-31 02-28 03-31 04-30 金盘科技 沪深300 分析师：张志邦 执业证书号：S0010523120004 邮箱：zhangzhibang@hazq.com 分析师：郑洋 执业证书号：S0010524110003 投资建议 我们预计 2025-2027 年公司营收分别为 86.90/109.49/138.40 亿元 （ ...

Investment Rating - The report maintains a "Buy" rating for Haier Smart Home, with a projected P/E ratio of 11/10/9X for the upcoming years [9]. Core Views - The company's Q1 performance slightly exceeded expectations, driven by domestic subsidies and resilient contributions from emerging markets, alongside the effectiveness of digital transformation in cost reduction and efficiency improvement [6][8]. - Revenue for Q1 reached 79.118 billion yuan, representing a year-on-year increase of 10.06%, while net profit attributable to the parent company was 5.487 billion yuan, up 15.09% year-on-year [8]. Revenue Analysis - Domestic sales supported by national subsidies and flexible contributions from emerging markets, with Q1 domestic and foreign sales growing by 7.8% and 12.6% year-on-year, respectively [8]. - Emerging markets showed significant growth, with North America, Europe, Middle East & Africa, South Asia, Southeast Asia experiencing year-on-year growth rates of approximately 0%, +30%, +50%, +30%, and +20%, respectively [8]. - The Casarte brand continued to perform well, with a year-on-year growth of over 20% in Q1 [8]. Profitability - The gross margin for Q1 was 25.4%, a slight increase of 0.1 percentage points year-on-year, while the net profit margin was 6.93%, up 0.3 percentage points year-on-year [8]. - Cost reduction and efficiency improvements were attributed to supply chain optimization and digital transformation, leading to better gross and expense ratios [8]. Financial Forecast - The report maintains previous profit forecasts, projecting revenues of 304.093 billion yuan, 316.502 billion yuan, and 327.129 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 6.3%, 4.1%, and 3.4% [8]. - Net profit attributable to the parent company is expected to reach 21.254 billion yuan, 23.346 billion yuan, and 24.804 billion yuan for the same years, reflecting year-on-year growth rates of 13.4%, 9.8%, and 6.2% [8]. Shareholding Plan - The company announced a shareholding plan for 2025, targeting a scale of 757 million yuan, aimed at certain directors, senior management, and core technical personnel, with performance targets set for ROE exceeding 17.7% for 2025-2026 [8].